Home » Topics » BioWorld Science

BioWorld Science
RSS

New G2019S mutant leucine-rich repeat kinase 2 inhibitors discovered at Merck & Co.

March 30, 2022

Prokineticin-2 levels are dramatically decreased in sepsis and septic shock

March 30, 2022

PPAR-delta/beta modulates colon tumorigenesis

March 30, 2022

Gain-of-function study identifies T-cell boosters

March 29, 2022

Novel NR4A1 antagonists show antitumor activity in syngeneic mouse model of colon cancer

March 29, 2022

Flavonoids as nuclear receptor 4A1 ligands for treating rhabdomyosarcoma

March 29, 2022

Artelo collaborates with Trinity College Dublin to better understand FABP inhibition in cancer

March 29, 2022

LNP formulation development and production service launched by eTheRNA Manufacturing

March 29, 2022

PF-07038124: a topical PDE4 inhibitor for atopic dermatitis and plaque psoriasis

March 29, 2022

Elicio Therapeutics' TLR9 agonist AMP-CpG induces potent immune and antitumoral effects

March 29, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...